Psychedelic Revival Learning Series Resources
Resources for each of the events in our Psychedelic Revival event series are below.
Session #1: An Introduction to Psychedelics
January 19, 2022
For nurses interested in receiving continuing education credits for the Psychedelics Revival Learning series, live participation for each session is required. Eligible participants must complete and submit the survey at the link below before midnight on January 23, 2022 to receive CE credit.
- Bloomberg: Why Psychedelics, Big in the 1960s, Are Drawing New Interest Now
- Newsweek: Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
- Nursing & Sacred Medicine
- New York Times: The Promises and Perils of Psychedelic Health Care
- WebMD: A Long, Strange Trip: Psychedelics Meet Mainstream Medicine
- The Guardian: A brief history of psychedelic psychiatry
- MAPS: Indigenous Reciprocity Initiative of the Americas: A Respectful Path Forward for the Psychedelic Movement
- American Journal of Nursing: Psychedelic-Assisted Therapy
- Psychedelic.Support
• Anderson, F.D.(1967). Murder suspect tells of LSD use. New York Times October 10: 37.
• Anonymous. (1967). Jury told Kessler took an LSD cube before the slaying. New York Times October 12: 46.
• Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., … Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: An interpretive phenomenological analysis. Journal of Humanistic Psychology, 57, 354-388.
• Bieberman, L. (1968). Phanerothyme: A western approach to the religious use of psychochemicals. The Psychedelic Information Center Bulletin, pp. 1-15.
• Blewett, D.B. & Chwelos, N. 1959. Handbook for the therapeutic use of LSD-25. Unpublished pamphlet.
• Bogenschutz, M., Forcehimes, A., Pommy, J., Wilcox, C., Barbosa, P., & Strassman, R. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299.
• Burroughs, W. (1963) Yage letters.City Lights
• Carhart-Harris, R., Bolstridge, M., Rucker, J., Day, C., Erritzoe, D., Kaelen, M., … Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.
• Cohen, M.M.; Hirschorn, K. & Frosch, W.A. 1967. In vivo and in vitro chromosomal damage induced by LSD-2S. New England Journal ofMedicine 277 (20): 1 043-49.
• Cohen, M.M.; Marinello, M.J. & Back, N. 1967. Chromosomal damage in human leukocytes induced by lysergic acid diethylamide. Science ISS (3768): 1417-19.
• Cohen, S. 1966. A classification of LSD complications. Psychosomatics 7:182-86.
• Cohen, S. 1964. Drugs of Hallucination. London: Seeker and Warburg.
• Cohen, S. 1960. LSD: Side effects and complications. Journal of Nervous and Mental Disease 1 30:30-40.
• Cohen, S. (1960). Notes on the hallucinogenic state. International Record of Medicine, 173(6), 380-387.
• Cohen, S. (1964a). The beyond within. New York: Atheneum.
• Cohen, S. (1964b). Drugs of hallucination. London: Secker and Warburg.
• Cohen, S. & Ditman, K. 1963. Prolonged adverse reactions to lysergic acid diethylamide. Archives of General Psychiatry 8:47S-80.
• Cohen, S. & Ditman, K. 1 962. Complications associated with LSD-2S. Journal of the American Medical Association 181 (2): 161 -62.
• Cole, J.O. 1968. Problems facing the investigator. Paper presented at the Sixth Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
• Cole, J.O. 1961. Drugs and control of the mind. In: S. Farber & R.H.L. Wilson (Eds.) Man and Civilization: Control ofthe Mind. New York: McGraw Hill.
• Cole, J.O. & Katz, M.M. 1964. The psychotomimetic drugs. Journal of the American Medical Association I 87 (10): 758-59.
• “Corporation Fires Richard Alpert for Giving Undergraduates Drugs: First Dismissal Under Pusey”, Harvard Crimson, May 28, 1963
• Cowan, Eliot. (2014). Plant spirit medicine. Boulder, CO: Sounds True Inc.
• Dahlberg, C.C. 1966. LSD: Tamed for research. Science 153 (September 30): 844.
• Danforth, A., Grob, L., Struble, C., Feduccia, S., Walker, C., Jerome, A., … Emerson, N. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137-3148.md
• Davidson, B. 1967. The hidden evils of LSD. Saturday Evening Post August 12: 19-23.
• Dishotsky, N.J.; Loughman, W.O.; Mogar, R. E. & Lipscomb, W.R. 1971.
• Ditman, K. S., & Whittlesley, J. R. B. (1959). Comparison of the LSD-25 experience and delirium tremens. A. M. A. Archives of General Psychiatry, 1, 63-73.
• Dodgson, R. (2013)It’s All Kind of Magic: The Young Ken Kesey. University of Wisconsin Press
• Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., … Wolfson, P. (2019). Ketamine Assisted Psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs, 51(2), 189-198.
• Elkes, C; Elkes, J. & Mayer-Gross, W. 1954. Hallucinogenic drugs. Lancet (April 2): 719.
• Editors. 1 967. Radiomimetic properties of LSD. New England Journal of Medicine 277 (20): 1 090-9 1.
• Editors. 1966. Further consideration of the dangers of LSD. New England Journal of Medicine 274:836.
• Editors. 1 965. LSD-A dangerous drug. New England Journal of Medicine 273:1 280.
• Epstein, H.J. (1977). Agency of fear: The story of how the Drug Enforcement Administration came to be. G. P. Putnam and Sons
• Fadiman, J. 1967. Treatment of alcoholism with lysergide. Quarterly Journal ofStudies on Alcoholism 28 (I): 146-47.
• Farnsworth, D. 1 963. Hallucinogenic agents. Journal of the American Medical Association 185 (I I): 878-79.
• Farnsworth, D. (1967). The drug problem among young people. West Virginia Medical Journal, 63(12), 433-437.
• Farrell, B. 1966. Scientists, theologians, mystics swept up in a psychic revolution. Life 60 (12): 30-33.
• Faudree, P. (2015). Tales from the Land of Magic Plants: Textual Ideologies and Fetishes of Indigeneity in Mexico’s Sierra
• Feduccia, A., Holland, J., & Mithoefer, M. (2018). Progress and promise for the MDMA drug development program. Psychopharmacology,235(2), 561-571.
• Feld, M.; Goodman, J. & Guido, J.A. 1958. Clinical and laboratory observations on LSD-25. Journal of Nervous and Mental Disease 126: 1 76-83.
• Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T. & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513-20.
• Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening
disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology, 29(1), 57-68.
• Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., . .Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197.
• Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283.
• Grinker, R.R. 1 964. Bootlegged ecstasy. Journal of the American Medical Association 187 (10): 768-69.
• Grinker, R.R. 1 963. Lysergic acid diethylamide. Annals of General Psychiatry 8 (5): 425.
• Grinspoon, L., & Bakalar, J. L. (1979). Psychedelic drugs reconsidered. New York: Basic Books.
• Grob, C. & Grigsby, J (2021) Handbook of Medical Hallucinogens. Guildford Press.
• Hoffer, A. (1967). A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In H. A. Abramson (Ed.), The use of LSD in psychotherapy and alcoholism (pp. 407-433). Indianapolis: Bobbs-Merrill.
• Hoffer, A., & Osmond, H. (1967). The hallucinogens. New York: Academic Press.
• Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.
• Kleps, A. (1975). Millbrook. Oakland, CA: Bench Press.
• Kolp, E., Krupitsky, E., Sylvester, M., Kolp, A., Friedman, H. L., Jansen, K., & Young, M. S. (2015). Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications. International Journal of Transpersonal Studies.
• Krippner, S., & Winkelman, M. (1983) Maria Sabina: Wise lady of the mushrooms. Journal of Psychoactive Drugs, 15(3), 225-228, DOI: 10.1080/02791072.1983.10471953 .
• Labate, B. C., & MacRae, E. (Eds.). (2010). Ayahuasca, rital and religion in Brazil. New York, NY: Equinox.
• Leary, T., Metzner, R., & Alpert, R. (1964). The psychedelic experience: A manual based on the Tibetan Book of the Dead. New Hyde Park, NY: University Books.
• Leary, T. (1964a). How to change behavior. In D. Solomon (Ed.), LSD: The consciousness-expanding drug (pp. 97-113). New York: G. P. Putnam’s Sons.
• Li, L. & Vlisides, P. E. (2016). Ketamine: 50 years of modulating the mind. Frontiers in Human Neuroscience, 10, 612.
• Liester, M. (2014). A review of lysergic acid dethylamide (LSD) in the treatment of addictions: Historical perspectives and future prospects. Current Drug Abuse Reviews, 7, 146-156.
• “Linkletter Blames LSD For Death Of Daughter”. The Morning Record. 1969-10-06. p. 1.
• Long. S. 1972. Does LSD induce chromosomal damage and malformations? A review of the literature. Teratology 6: 72-90.
• LSD and genetic damage. Science 172: 43 1-39.
• Mangini, M. (2021). Unseen Women in Psychedelic History. Journal of Humanistic Psychology, 00221678211029186.
• Mazateca. Comparative Studies in Society and History, 57(3), 838-869.
• Morris, S. J. (2014) Clare, In love and war. Vanity Fair.
• McClelland, D. C. (1961). Some social reactions to the psilocybin research project. Cambridge MA: Harvard Center for Research in Personality.
• Morgan, C., Muetzelfeldt, L., & Curran, H. (2009). Ketamine use, cognition and psychological wellbeing: A comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction, 104(1), 77-87. doi:10.1111/j.1360- 0443.2008.02394.x
• Nichols, D. E., & Walter, H. (2021). The history of psychedelics in psychiatry. Pharmacopsychiatry, 54(04), 151-166.
• Noorani, T., Garcia-Romeu, A., Swift, T., Griffiths, R., & Johnson, M. (2018). Psychedelic therapy for smoking cessation: Qualitative
analysis of participant accounts. Journal of Psychopharmacology, 32(7), 756-769.
• Novak, S. 1997. LSD before Leary. Isis 88:87- 110
• Powell, G. (1967) LSD changed Cary Grant’s private life. National Police Gazette. December, 3-4
• Osmond, H. 1 957. A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Science 66 (3): 4 18-34.
• Pahnke, W. N., & Richards, W. A. (1966). Implications of LSD and experimental mysticism. Journal of Religion and Health, 5, 175-208.
• Parrott, A. (2014). MDMA is certainly damaging after 25 years of empirical research: A reply and refutation of Doblin et al . (2014. Human Psychopharmacology: Clinical and Experimental, 29(2), 109-119.
• Ross, S. Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.
• Schultes, R. E., Hofmann, A., & Ratsch, C. (1998). Plants of the Gods: Their sacred, healing, and hallucinogenic powers. Rochester, VT: Healing Arts.
• Wolfe, T. (1968). The electric kool-aid acid test. New York: Farrar, Strauss and Giroux.
Session #2: What Happens in Psychedelic Therapy?
February 2, 2022
For nurses interested in receiving continuing education credits for the Psychedelics Revival Learning series, live participation for each session is required. Eligible participants must complete and submit the survey at the link below before midnight on February 6, 2022 to receive CE credit.
- What Happens in Psychedelic Therapy?
- Andrew Penn on Psychedelics Today Podcast
- Psychedelic Therapy Is Having Moment - Here’s What You Need to Know
- Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
- One Man’s Psychedelic Journey to Confront His Cancer
- Nurses in Psychedelics, Naturals Caring for Patients in Non-Ordinary States of Consciousness
- Clinical Trial Information
Session #3: Psychedelic Neuroscience and Pharmacology
February 15, 2022
For nurses interested in receiving continuing education credits for the Psychedelics Revival Learning series, live participation for each session is required. Eligible participants must complete and submit the survey at the link below before midnight on February 20, 2022 to receive CE credit.
- An Introduction to Psychedelic Neuroscience
- Psychedelics Promote Structural and Functional Neural Plasticity
- Psilocybin-Assisted Mindfulness Training Modulates Self-Consciousness and Brain Default Mode Network Connectivity with Lasting Effects
-
Altered Network Hub Connectivity After Acute LSD Administration
- Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial
-
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults - Clinical Trial Information
Session #4: The Current Landscape of Psychedelic Medicine - How to Get Involved
March 2, 2022
For nurses interested in receiving continuing education credits for the Psychedelics Revival Learning series, live participation for each session is required. Eligible participants must complete and submit the survey at the link below before midnight on March 6, 2022 to receive CE credit.
Session #5: The Future of Psychedelic Medicine
March 16, 2022
For nurses interested in receiving continuing education credits for the Psychedelics Revival Learning series, live participation for each session is required. Eligible participants must complete and submit the survey at the link below before midnight on March 20, 2022 to receive CE credit.
- PRATI - Psychedelic Research and Training Institute
- The Battle Over Psychedelic Therapy’s Future
- Psychedelic Drug Policy Reform in 2021
- TED Health: The future of Psychedelic Medicines and Healthcare
- NYT Guest Essay by Michael Pollan: How Should We Do Drugs Now?
- Scientific American: A Strategy for Rescheduling Psilocybin
- Vital Signs Podcast with Dr. Stephen Ross: A Psychiatrist’s Mission to Bring Psychedelic Drugs into the Mainstream
- The Guardian: Ecstasy, LSD and magic mushrooms: are these drugs the future of therapy?
- Psychedelics Today Podcast with Dr. Rachel Yehuda: Research Trials and the Future of Psychedelic Neuroscience
Session #6: Access to Psychedelic Medicine
March 30, 2022
For nurses interested in receiving continuing education credits for the Psychedelics Revival Learning series, live participation for each session is required. Eligible participants must complete and submit the survey at the link below before midnight on April 3, 2022 to receive CE credit.
- The Cost of Exclusion in Psychedelic Research
- Announcing MAPS’ Health Equity Plan
- Who Will Benefit from Psychedelic Medicine?
- Equity in Psychedelic Therapies
- Using Psychedelics to Treat Veterans’ PTSD
- Science Names MDMA-Assisted Therapy for PTSD a 2021 Scientific Breakthrough of the Year
- 2021 Breakthrough of the Year
- Psychedelics Can Change Humanity for the Better. It’s Time to Unlock Their Power
- 9 Women of Color Creating A More Inclusive Psychedelic Movement
- Psychedelic Justice: Creating a Socially Just Psychedelic Renaissance
- Could Group Therapy Get a Boost From Psychedelics?
- SoundMind Opens a Psychedelic Clinic in West Philly as Momentum Builds for Treatment of Depression, PTSD with Mind-Altering Drugs
- The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
- Leading US Company to Offer Staff Psychedelic Therapy as Employee Healthcare Benefit
Session #7: Personal Stories of Transformation
April 13, 2022
Related Links
THE INFORMATION PRESENTED AS PART OF THIS LEARNING SERIES IS FOR EDUCATIONAL PURPOSES ONLY. IT SHOULD NOT BE TAKEN AS MEDICAL OR LEGAL ADVICE. PENN NURSING AND THE SPEAKERS SUPPORTING THIS LEARNING SERIES DO NOT ENDORSE THE USE OF ILLEGAL SUBSTANCES.
